Opinion
Video
Primary and Secondary Endpoints
Panelists discuss how the primary endpoint of the Effisayil 2 trial focused on the time to first GPP flare, while secondary endpoints assessed flare severity, quality of life, and inflammatory markers, providing a comprehensive evaluation of spesolimab's impact on GPP management.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
